Article Details

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready ...

Retrieved on: 2021-07-19 12:22:30

Tags for this article:

Click the tags to see associated articles and topics

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready .... View article details on hiswai:

Excerpt

Suvratoxumab monoclonal antibody (mAb) for prevention of pneumonia has been licensed from AstraZeneca. Suvratoxumab extends Aridis' ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up